wegovy Pill Shows 16.6% Weight loss in Landmark Obesity Study
Table of Contents
A new oral formulation of Wegovy, containing semaglutide 25 mg, has demonstrated an average weight loss of 16.6% in adults with obesity, according to results published in The New England Journal of Medicine. This once-daily pill offers a potential alternative to the currently available injectable version and could significantly expand access to effective obesity treatment.
A Potential Game-Changer for Weight Management
Novo Nordisk has submitted the oral semaglutide treatment to the US Food and Drug Governance (FDA) as the first oral GLP-1 therapy for long-term weight management. Production of the medication is already underway at the company’s facilities in the United States, signaling confidence in a swift rollout pending regulatory approval. The study findings reveal that approximately one in three participants experienced weight loss of 20% or more with the oral formulation.
OASIS 4 Trial: Detailed Results
The phase 3 OASIS 4 trial, a 64-week randomized, double-blind, placebo-controlled study, involved 307 adults with obesity or overweight and at least one weight-related condition, excluding those with diabetes. Participants receiving oral semaglutide 25 mg,in conjunction with lifestyle changes,achieved an average weight loss of 16.6% compared to 2.7% in the placebo group. Notably, 34.4% of those on semaglutide lost at least 20% of their body weight, versus just 2.9% in the placebo group.
Even when accounting for varying levels of trea
Mild Side Effects and Established Safety Profile
The OASIS 4 trial reported that gastrointestinal side effects where generally mild to moderate and temporary. The most common side effects were nausea (46.6% compared with 18.6% for placebo) and vomiting (30.9% compared with 5.9% for placebo). Permanent discontinuation due to adverse events occurred in 6.9% of participants on semaglutide and 5.9% of those on placebo. serious adverse events were less frequent in the semaglutide group (3.9%) compared to the placebo group (8.8%).
These findings reinforce the established safety profile of semaglutide, supported by over 37 million patient-years of use globally.
Wegovy and the future of Obesity Treatment
Novo Nordisk submitted a New Drug Application (NDA) to the FDA in Febuary, with a review expected to conclude by the end of 2025. Currently,no oral GLP-1 therapies are approved for weight management.Wegovy, currently available as a 2.4 mg injection, is already approved in the European Union as an adjunct to diet and exercise for adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with weight-related conditions, and for adolescents aged 12 and older with obesity.
The injectable form has demonstrated reductions in major cardiovascular events, improvements in heart failure symptoms, enhanced physical function, and reduced knee osteoarthritis pain. In the US, Wegovy injection is approved for similar indications, and also to lower the risk of cardiovascular events in adults with obesity and established heart disease. It is indeed critically important to note that semaglutide injection carries a Boxed Warning regarding potential thyroid tumors, and is not suitable for individuals with a personal or family history of certain endocrine conditions. The oral formulation, semaglutide 25 mg, is not yet approved in either the US or Europe.
The OASIS 4 trial included a 12-week dose escalation phase, a 52-week treatment period, and a 7-week follow-up. Participants were assigned in a 2:1 ratio to either semaglutide or placebo, alongside lifestyle counseling and dietary modifications.
Obesity is recognized as a complex, chronic, and progressive disease influenced by biological, genetic, social, and environmental factors, rather then simply a matter of willpower. The development of oral semaglutide represents a significant step forward in addressing this widespread health challenge and providing more accessible treatment options for those in need.
Worth a look
- Daily Lotto Results: Wednesday, 12 August 2026 (newsy-today.com)
